• Elicio Therapeutics’ Phase 2 AMPLIFY-7P trial of camupepimut in pancreatic cancer missed its primary disease-free survival endpoint.
• Results were presented at the ESMO Congress 2026 in Madrid and simultaneously published in Nature Medicine.
• Prespecified subgroup analyses favored treatment, while an imbalance in baseline recurrence risk complicated interpretation of the overall results.
• Camupepimut was generally well tolerated, with no new safety signals or adverse events leading to treatment withdrawal.
• The company plans FDA discussions on a potential Phase 3 trial, including patient stratification, treatment duration and combination strategies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230900PRIMZONEFULLFEED9851958) on October 23, 2026, and is solely responsible for the information contained therein.